SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is experiencing a volatile relief rally driven by a combination of a derivatives-led short squeeze and shifting market sentiment regarding U.S.-Iran ceasefire negotiations. The community remains heavily divided, with bulls pointing to institutional accumulation as a foundation for growth while bears dismiss the price action as a temporary trap ahead of potential geopolitical escalation.

Lightwave Logic, Inc. is a development stage company which engages in the commercialization of electro-optic photonic devices. The firm offers the P2ICTM technology platform which uses in-house proprietary organic polymers. Its products include electro-optical modulation devices and proprietary polymer photonic integrated circuits. The company was founded on June 24, 1997 and is headquartered in Englewood, CO.

Lightwave Logic Inc

Lightwave Logic is seeing a massive surge in investor interest driven by a strategic development agreement with Tower Semiconductor, which aims to integrate its high-speed polymer modulators into a silicon photonics platform for AI and data center applications. The community is actively debating the stock's long-term potential as a critical AI infrastructure play versus concerns over its pre-revenue status and historical volatility, with many users focused on whether the current momentum will lead to a broader industry shift or if the stock is vulnerable to a classic pump-and-dump cycle.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is seeing intense community focus as traders debate the company's buyout potential and long-term valuation against larger competitors like Lilly and Novo Nordisk. Investors are actively analyzing recent clinical trial progress and the significant short interest, while weighing the impact of macro-geopolitical pressures on the stock's near-term price volatility.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is trending as traders analyze its price action relative to broader market volatility, with community sentiment split between short-term bearishness regarding macro uncertainties and long-term bullishness fueled by institutional interest and institutional accumulation patterns. The discourse centers on critical support levels, potential structural upgrades like the Ethereum Economic Zone, and how the asset is navigating geopolitical tensions that are currently impacting the wider crypto and energy sectors.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is currently trending as shareholders voice intense frustration over the stock's lack of upward momentum, fueling renewed speculation regarding a potential buyout or urgent partnership deal. The community is actively debating the recent leadership changes in R&D and pressuring activist investor Shah Capital to force a strategic sale, while simultaneously highlighting the persistent suppression of share price by short interest and derivative market mechanics.

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvana is facing intense polarization as it navigates a potential stock split alongside persistent skepticism from short sellers who cite weakening loan performance and broader economic headwinds. The community remains deeply divided, with vocal bears focusing on potential accounting irregularities and valuation concerns, while optimistic traders continue to monitor volatility and institutional positioning for signs of momentum.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Berkeley Heights, NJ.

Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals is facing intense community debate as investors weigh concerns over potential dilution and future stock splits against optimism surrounding the commercial traction and insurance coverage expansion of their lead product, Tonmya. While some shareholders are selling amid downward price pressure and a history of capital raises, others are aggressively buying the dip, citing strong long-term pipeline fundamentals and recent insider share purchases as evidence of an impending turnaround.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is rallying as excitement builds around the historic Artemis II moon mission and the potential implications of a major SpaceX IPO, leading to increased trading volume and bullish momentum. The community is actively discussing these space-sector catalysts, with many investors closely tracking mission updates while balancing the long-term potential of lunar infrastructure contracts against the volatility typical of this high-growth sector.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending as investors and the community closely monitor escalated geopolitical rhetoric and the potential for a widened conflict in the Middle East, with intense debate centering on the stock's exposure to administration policy shifts and volatile energy markets. The discussion is heavily influenced by social media reactions to current events, ranging from extreme bullish optimism regarding defense and oil policy to sharp skepticism concerning the economic impact of ongoing international instability.

Bonk is a dog-themed memecoin on the Solana blockchain, launched on Christmas Day 2022 to revitalize the Solana community following the FTX collapse. Created by an anonymous team of 22 Solana developers and builders, Bonk distributed 50% of its total 100 trillion token supply via airdrop to community members including NFT collectors, developers, and artists.   The project positions itself as "the first Solana dog coin for the people, by the people," explicitly rejecting venture capital backing in favor of grassroots community ownership. What sets Bonk apart from other memecoins is its combination of fair launch mechanics, extensive ecosystem integration, and active deflationary strategy.   Built on Solana, BONK benefits from fast transaction speeds and low fees that make it practical for everyday use. Native products include LetsBonk.fun (a memecoin launchpad that briefly became Solana's market leader in 2025, surpassing Pump.fun with over 78% market share), BonkSwap (a decentralized exchange) and BonkBot (a Telegram trading bot with built-in burn mechanics).   BONK is available across 10 blockchain networks and listed on major exchanges including Binance, Coinbase, Kraken, and Robinhood. Governance is handled by BonkDAO, which holds 15% of the token supply and makes decisions through on-chain voting.   The community has organized several major burn events, most notably the December 2024 BURNmas campaign that destroyed 1.69 trillion tokens worth over $50 million. In September 2025, Nasdaq-listed Safety Shot, Inc. formed BONK Holdings LLC and acquired over 2.5% of the circulating supply (valued at $55-63 million), making BONK one of the first memecoins to attract formal corporate treasury adoption. Core contributor Nom was appointed to Safety Shot's board, and the company holds a 10% revenue share in LetsBonk.fun.  As with all memecoins, BONK is a highly speculative asset with substantial volatility. Its value is primarily driven by community sentiment, social media momentum, and meme culture rather than traditional utility.   The anonymous team, while common in the memecoin space, means investors should exercise appropriate caution. Despite these risks, Bonk has established itself as one of the most successful community-driven tokens in the Solana ecosystem, approaching 1 million unique holders and expanding from a simple memecoin into meaningful DeFi infrastructure.

BONK

BONK is experiencing heavy community engagement as investors debate its long-term potential, with active discussions focusing on upcoming token burns, holder growth milestones, and its role within the broader meme coin landscape. Sentiment remains deeply divided, characterized by a mix of high-conviction accumulation strategies from long-term bulls and skeptical claims of market volatility.

statis crypto Watchlist

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The company added that the acquisition will embed Modella AI’s multi-modal foundation models and AI agents into AstraZeneca’s oncology research and development environment.</li><li>Separately, AstraZeneca announced that the first patient has been dosed in a late-stage trial evaluating Datroway compared to docetaxel in patients with certain types of lung cancer.</li></ul>Pharmaceutical giant AstraZeneca (AZN) has purchased Boston-based biomedical AI company Modella AI for an undisclosed sum, according to a statement from the startup on Tuesday.Modella <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20260113561240/en/Modella-AI-Announces-Acquisition-by-AstraZeneca-to-Advance-AI-Driven-Oncology-RD-at-Global-Scale">said</a> that the buyout is aimed at expanding the two companies’ existing collaboration for advancing the application of artificial intelligence across the drugmaker’s cancer drug portfolio.The company added that the acquisition will embed Modella AI’s multi-modal foundation models and AI agents into AstraZeneca’s oncology research and development environment. This would allow for the generation of new insights and allow for greater automation across workflows, the company said.Shares of AZN traded marginally in the green at the time of writing.<h2 class="st-heading-2">Partnership To Acquisition</h2>Modella announced a multi-year deal with AstraZeneca in 2025 aimed at integrating its generative and agentic AI platform into AstraZeneca’s oncology research and development organization.The collaboration was aimed at supporting efforts to accelerate clinical development and enhancing biomarker discovery.<h2 class="st-heading-2">First Patient Dosing In New Late-Stage Trial</h2>Separately, AstraZeneca announced earlier on Tuesday that the first patient has been dosed in a late-stage trial evaluating Datroway compared to docetaxel in patients with certain types of locally advanced or metastatic nonsquamous non-small cell lung cancer. Lung cancer is the most common cancer globally.Datroway, meanwhile, is a cancer drug jointly developed and commercialized by AstraZeneca and Daiichi Sankyo.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around AZN stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.A Stocktwits user opined that AstraZeneca must try to acquire smaller drugmaker Omeros Corp.<stembedurl>https://www.stocktwits.com/resq1/message/641646825</stembedurl><a href="https://stocktwits.com/symbol/AZN">AZN stock</a> has gained 43% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/fund-manager-flags-concerns-about-tesla-dwindling-delivery-numbers-high-pe-ratio/cmUXXNkR4Ia">Fund Manager Flags Concerns About Tesla’s Dwindling Delivery Numbers, Notes High P/E Ratio</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The international biopharmaceutical company AstraZeneca office building in Shanghai, China on June 27, 2025. 

AstraZeneca Buys Boston-Based Startup In Fresh AI Push For Cancer Pipeline

Modella said that the buyout is aimed at expanding the two companies’ existing collaboration for advancing the application of artificial intelligence across the drugmaker’s cancer drug portfolio. 

Equity

Modella said that the buyout is aimed at expanding the two companies’ existing collaboration for advancing the application of artificial intelligence across the drugmaker’s cancer drug portfolio. 


<ul class="summary-bullets"><li>MSCI, earlier had proposed to exclude crypto treasury firms from its global indexes.</li><li>MSCI said current index treatment of DATCOs identified in the preliminary list will remain unchanged.</li><li>Shares of DAT firms rallied after the announcement.&nbsp; &nbsp;</li></ul>MSCI said on Tuesday that it has decided not to implement the proposal to exclude digital asset treasury companies (DATCOs) from the MSCI Global Investable Market Indexes (MSCI Indexes) as part of the February 2026 Index Review.&nbsp;DATCOs currently included in MSCI Indexes will continue to remain, provided they meet all other index inclusion requirements, it said.&nbsp;However, MSCI intends to open a broader consultation on the treatment of non-operating companies in general. MSCI had earlier proposed to exclude crypto treasury firms from its global indexes. &nbsp;The consultation results were scheduled to be announced by January 15, 2026.&nbsp;Shares of one of the biggest DAT companies, Michael Saylor-backed Strategy, rallied more than 5% after the announcement. Meanwhile, Bitmine Immersion shares jumped 2.3% and Strive Asset Management shares were up 1.9% during after market hours of trading.&nbsp;MSCI said that the current index treatment of DATCOs identified in the preliminary list published by MSCI of companies whose digital asset holdings represent 50% or more of their total assets will remain unchanged.&nbsp;MSCI did flag that feedback from the consultation confirmed institutional investor concern that some DATCOs exhibit characteristics similar to investment funds, which are not eligible for inclusion in the MSCI Indexes.&nbsp;<h2 class="st-heading-2">DATs Rise</h2>Firms globally are adopting DATs to put digital currencies on their balance sheets, as interest in the sector continues to surge.&nbsp;Easing regulations around cryptocurrencies and broader acceptance of tokens for transactions has also helped several companies turn their operations into DATs or launch their subsidiaries as DATs.&nbsp;One of the biggest DAT companies is Michael Saylor-backed Strategy (MSTR), which began buying bitcoin in 2020 and has been continuing to do so ever since. Notably, the number of DAT companies has expanded over the years.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around MSTR trended in ‘extremely bullish’ territory amid ‘high’ message volume.For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

This photo shows a smartphone screen displaying the Bitcoin cryptocurrency logo.

MSTR, BMNR, ASST Shares Rally After MSCI Decides To Not Exclude Digital Asset Treasury Firms From Its Indexes

Digital asset treasury companies currently included in MSCI Indexes will continue to remain, provided they meet all other index inclusion requirements, it said. 

Mag 7 Beats S&P 500 in Q3: Buy These 3 ETFs to Tap Their Strength

ETFs like XLG provide a diversified way to benefit from the Mag 7's Q3 earnings surge and the positive momentum expected going forward.

AstraZeneca (AZN) on Wednesday announced the unveiling of its expanded manufacturing facility in Texas aimed at doubling the production of its drug Lokelma.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20251014866366/en/AstraZeneca-unveils-expanded-manufacturing-facility-in-Texas">invested</a> $445 million to expand the facility, it said. The unveiling <a href="https://stocktwits.com/news-articles/markets/equity/astrazeneca-announces-4.5-billion-dollar-investment-in-virginia/ch67yQKR31I">follows</a> the groundbreaking last week at the drugmaker’s $4.5 billion manufacturing facility in Albemarle County, Virginia. &nbsp;The investments are part of the company’s commitment to invest $50 billion in the U.S. by 2030, with the goal of reaching $80 billion in total revenue by then.The facility in Coppell, which employs more than 250 people, is the sole global manufacturing facility for AstraZeneca’s Lokelma, a prescription medicine for the treatment of high levels of potassium in the blood in adults, a condition known as hyperkalemia.The facility supplies the drug to more than 50 countries worldwide. <a href="https://stocktwits.com/symbol/AZN">AstraZeneca</a> said that through the expansion and development of a new 9,000 square foot building, two novel manufacturing lines will be added, along with enhancements to support drug substance and drug product laboratory testing, warehousing, additional manufacturing utilities, and administrative space.The increased investment in the U.S. by drugmakers follows President Donald Trump’s push to move pharmaceutical manufacturing to American soil. Last month, President Trump announced on Truth Social that the United States will impose a 100% tariff on branded and patented pharmaceutical products effective October 1, unless manufacturers actively build plants in the country. Trump is also pressuring drugmakers to lower drug prices in the U.S. to levels comparable to those paid by other wealthy nations.On Stocktwits, retail sentiment around AZN stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.AZN stock is up by 29% this year and by about 8% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-says-oral-glp-1-drug-reduced-blood-sugar-levels-in-two-late-stage-trials/ch6nxr4R3Nm">Eli Lilly Says Oral GLP-1 Drug Reduced Blood Sugar Levels In Two Late-Stage Trials</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

AstraZeneca Unveils Expanded Facility In Texas Aimed At Doubling Production Of Hyperkalemia Drug

The facility in Coppell, which employs more than 250 people, is the sole global manufacturing facility for the company’s Lokelma. 

Drugmaker AstraZeneca (AZN) on Thursday said that it will invest $4.5 billion in a new manufacturing facility in Virginia amid President Donald Trump’s push to move pharmaceutical manufacturing to American soil.The investment is $500 million more than initially planned and is intended to support the enhanced manufacturing capability of a broader range of medicines, including weight management, metabolic, and cancer technologies, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20251009456597/en/AstraZeneca-plans-to-increase-investment-and-scope-of-its-Virginia-manufacturing-facility-to-%244.5-billion-creating-3600-new-jobs">said.</a>The new facility will be located at Rivanna Futures in Albemarle County, and the company expects the facility to create 600 skilled jobs and an additional 3000 jobs to support the facility’s construction. The construction will start immediately, and the facility is expected to be operational in the next four to five years, the company added.The new announcement is part of the company’s commitment to invest $50 billion in the U.S. by 2030, with the goal of reaching $80 billion in total revenue by then. AstraZeneca CEO Pascal Soriot on Thursday noted that the investment in Virginia is the largest in the company’s history.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/AZN">AZN stock</a> stayed within the ‘neutral’ territory over the past 24 hours, while message volume dropped from ‘normal’ to ‘low’ levels.<figure class="image"><img style="aspect-ratio:996/126;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_09_at_1_46_59_PM_png_5e85c683cb.webp" alt="AZN's Sentiment Meter and Message Volume as of 1:47 p.m. ET on Oct. 09, 2025 | Source: Stocktwits" width="996" height="126"><figcaption>AZN's Sentiment Meter and Message Volume as of 1:47 p.m. ET on Oct. 09, 2025 | Source: Stocktwits</figcaption></figure>Last month, President Trump announced on Truth Social that the United States will impose a 100% tariff on branded and patented pharmaceutical products starting October 1, unless manufacturers actively build plants in the country. Trump is also pressuring drugmakers to lower drug prices in the U.S. to levels comparable to those paid by other wealthy nations.Last month, AstraZeneca <a href="https://stocktwits.com/news-articles/markets/equity/astrazeneca-plans-ordinary-share-listing-in-us/chDub9CR376">announced</a> that it plans to list its ordinary shares on the New York Stock Exchange, replacing its existing U.S. listing of American Depositary Receipts (ADRs) on Nasdaq. The move is part of the company’s efforts to expand its access to capital, it had said, while noting that the U.S. has the world’s largest and most liquid public markets by capitalization.AZN stock is up by 31% this year and by 10% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-reportedly-intends-to-launch-longer-range-model-y-variant-in-china/ch67xJOR315">Tesla Reportedly Intends To Launch A Longer Range Model Y Variant In China</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

AstraZeneca Announces $4.5B Investment In Virginia 

The investment is $500 million more than initially planned, intended to support the enhanced manufacturing capability of a broader range of medicines, according to the company. 

AstraZeneca (AZN) on Friday launched an at-home delivery service for its Flumist influenza vaccine ahead of the upcoming flu season.Flumist is a vaccine that is sprayed into the nose to help protect against influenza in people aged two through 49 years. However, it may not prevent influenza in everyone who gets vaccinated, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20250815310613/en/FLUMIST-Influenza-Vaccine-Live-Intranasal-the-nations-only-nasal-spray-flu-vaccine-now-available-for-home-delivery">stated</a>.The vaccine was initially approved by the U.S. Food and Drug Administration in 2003. It can be self-administered by adults 18 to 49 years of age or administered by a parent or caregiver to individuals aged 2-17 years.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/AZN">AZN</a> rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume remained at ‘low’ levels.Adults aged 18 and older can visit the Flumist website and click to order, following which they will be directed to complete a medical screening questionnaire. These submissions will then be reviewed by a licensed healthcare provider with ASPN Pharmacies, an independent online specialty pharmacy, to determine eligibility.Once eligibility is confirmed and insurance verified, the vaccine will be prescribed and shipped to the consumer’s home by Polaris Pharmacy Services, a specialty pharmacy, in temperature-controlled packages.The vaccine will be delivered with clear administration instructions, storage guidance, and disposal instructions, AstraZeneca said. Once received, the vaccine should be stored in the refrigerator until use. The home delivery service will be available only in 34 states for the upcoming flu season due to local pharmacy laws, the company said. However, AstraZeneca is eyeing making the service available across all 48 contiguous states in future seasons.Flumist, meanwhile, will continue to be available in doctors’ offices and pharmacies for administration by healthcare professionals across the nation, the company added.AZN stock is up by 20% this year but down by about 8% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/big-short-investor-michael-burry-cuts-stake-in-estee-lauder/chsPoDFRdfW">‘Big Short’ Investor Michael Burry Cuts Stake In Estee Lauder By A Whopping 25% – More Details Inside</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

AstraZeneca Launches Home Delivery Service For Its Self-Administrable Flu Vaccine

Flumist can be self-administered by adults 18 to 49 years of age or administered by a parent or caregiver to individuals 2-17 years of age.

AstraZeneca (AZN) on Monday said that its investigational drug Baxdrostat reduced systolic blood pressure (SBP) compared with placebo at 12 weeks in a late-stage study evaluating the drug in uncontrolled or treatment-resistant hypertension.Nasdaq-listed shares of the company traded 0.3% higher at the time of writing.The reduction in systolic blood pressure was both statistically significant and clinically meaningful, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.astrazeneca.com/media-centre/press-releases/2025/baxdrostat-met-primary-and-all-secondary-endpts-in-baxhtn-phiii-trial.html">said</a> in a statement. Baxdrostat was generally well tolerated with a favourable safety profile in the trial, where patients with uncontrolled or treatment-resistant hypertension received the investigational drug or placebo on top of standard of care.According to <a href="https://stocktwits.com/symbol/AZN">AstraZeneca</a>, there are 1.3 billion people worldwide living with hypertension, a medical condition characterised by consistently high blood pressure levels, which can, over time, damage blood vessels and vital organs. While uncontrolled hypertension persists despite treatment with two or more medications, resistant hypertension, a more severe form, remains elevated despite treatment with three or more medications.A key contributor to hypertension is aldosterone, a hormone that increases blood pressure by promoting sodium and water retention. Baxdrostat is an oral, small-molecule investigational drug that inhibits an enzyme responsible for the synthesis of aldosterone in the adrenal gland.AstraZeneca acquired Baxdrostat through its purchase of CinCor Pharma, Inc. in February 2023. A contingent value right of $10 per share in cash is payable to former CinCor shareholders upon the submission of a new drug application either in the U.S. or Europe.AstraZeneca said on Monday that the data from the late-stage trial will be shared with regulatory authorities around the world, but did not detail when it will seek approval for the drug from the U.S. Food and Drug Administration.Baxdrostat is currently being investigated in clinical trials for hypertension, primary aldosteronism, chronic kidney disease, and the prevention of heart failure in high-risk hypertensive patients.On Stocktwits, retail sentiment around AstraZeneca is unchanged within the ‘neutral’ territory over the past 24 hours, accompanied by ‘low’ message volume.<figure class="image"><img style="aspect-ratio:1366/126;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_14_at_9_51_14_AM_png_716900ba11.webp" alt="AZN's Sentiment Meter and Message Volume as of 9:50 a.m. ET on July 14, 2025 | Source: Stocktwits" width="1366" height="126"><figcaption>AZN's Sentiment Meter and Message Volume as of 9:50 a.m. ET on July 14, 2025 | Source: Stocktwits</figcaption></figure>AZN stock was up by 9% this year but down by about 9% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/gsk-seeks-fda-approval-for-rsv-vaccine-in-more-adults/ch8ByXHR5Vp">GSK Seeks FDA Approval For RSV Vaccine In More Adults: Retail Sees No Reason To Shift Their Bullish Stance</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the AstraZeneca logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

AstraZeneca Stock Rises As Experimental Drug Lowers Blood Pressure In Late-Stage Study, Retail’s Yet To React

The reduction in systolic blood pressure in the trial was both statistically significant and clinically meaningful, the company said in a statement.

Invesco Exchange-Traded Fund Trust II - Invesco ESG NASDAQ 100 ETF

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

Current Price	$40.14
Prev Close	$40.09
Open	$39.29
Dividend Yield	N/A
50-Day Moving Average	$41.31
Beta	N/A
Avg. Volume	17,582.62
PE Ratio	N/A

52-Week High	$44.04
52-Week Low	$27.34
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

QQMG
Invesco ESG NASDAQ 100 ETF

Feed

News

Sentiment

Fundamentals

Info

Latest QQMG News

QQMGInvesco ESG NASDAQ 100 ETF